Erythrocyte-derived vesicles for circulating tumor cell capture and specific tumor imaging

Nanoscale ◽  
2019 ◽  
Vol 11 (25) ◽  
pp. 12388-12396 ◽  
Author(s):  
Ming Chen ◽  
Ao Liu ◽  
Bei Chen ◽  
Dao-Ming Zhu ◽  
Wei Xie ◽  
...  
Keyword(s):  
Tumor Cell ◽  
Tumor Imaging ◽  
Circulating Tumor Cell ◽  
Research Interest ◽  
Cell Capture ◽  
Specific Tumor ◽  
Precise Diagnosis ◽  
Diagnosis Of Cancer

The precise diagnosis of cancer remains a great challenge; therefore, it is our research interest to develop safe, tumor-specific reagents.

A Review of Enrichment Methods for Circulating Tumor Cells: from Single Modality to Hybrid Modality

The Analyst ◽  
2021 ◽  
Author(s):  
Yi Zhang ◽  
Yifu Li ◽  
Zhongchao Tan
Keyword(s):  
Early Diagnosis ◽  
Tumor Cell ◽  
Tumor Cells ◽  
Cancer Progression ◽  
Treatment Efficacy ◽  
Circulating Tumor Cell ◽  
Early Diagnosis Of Cancer ◽  
Diagnosis Of Cancer ◽  
Single Modality ◽  
Enrichment Methods

Circulating tumor cell (CTC) analysis as a liquid biopsy can be used for early diagnosis of cancer, evaluate cancer progression, and assess treatment efficacy. Enrichment of CTC from patient blood...

Abstract 4070: Development of circulating tumor cell capture from whole blood using beads and microfluidics

2012 ◽  
Author(s):  
Jason G. Kralj ◽  
Chanda Arya ◽  
Thomas P. Forbes ◽  
Matthew S. Munson ◽  
Samuel P. Forry
Keyword(s):  
Tumor Cell ◽  
Whole Blood ◽  
Circulating Tumor Cell ◽  
Cell Capture

scholarly journals Liquid Biopsy in Lung Cancer: A Perspective From Members of the Pulmonary Pathology Society

2016 ◽  
Vol 140 (8) ◽  
pp. 825-829 ◽  
Author(s):  
Lynette M. Sholl ◽  
Dara L. Aisner ◽  
Timothy Craig Allen ◽  
Mary Beth Beasley ◽  
Philip T. Cagle ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Tumor Cell ◽  
Liquid Biopsy ◽  
Media Coverage ◽  
Diagnostic Delay ◽  
Genetic Material ◽  
Circulating Tumor Cell ◽  
Lower Sensitivity ◽  
Cell Capture ◽  
Cellsearch System

Liquid biopsy has received extensive media coverage and has been called the holy grail of cancer detection. Attempts at circulating tumor cell and genetic material capture have been progressing for several years, and recent financially and technically feasible improvements of cell capture devices, plasma isolation techniques, and highly sensitive polymerase chain reaction– and sequencing-based methods have advanced the possibility of liquid biopsy of solid tumors. Although practical use of circulating RNA-based testing has been hindered by the need to fractionate blood to enrich for RNAs, the detection of circulating tumor cells has profited from advances in cell capture technology. In fact, the US Food and Drug Administration has approved one circulating tumor cell selection platform, the CellSearch System. Although the use of liquid biopsy in a patient population with a genomically defined solid tumor may potentially be clinically useful, it currently does not supersede conventional pretreatment tissue diagnosis of lung cancer. Liquid biopsy has not been validated for lung cancer diagnosis, and its lower sensitivity could lead to significant diagnostic delay if liquid biopsy were to be used in lieu of tissue biopsy. Ultimately, notwithstanding the enthusiasm encompassing liquid biopsy, its clinical utility remains unproven.

Sign in / Sign up

Export Citation Format

Share Document